On Sept. 19, the US Food and Drug Administration released a safety announcement on Mirapex (pramipexole), used to treat Parkinson’s disease and restless legs syndrome, and the possible risk of heart failure. The announcement states, “Because of the study limitations, FDA is not able to determine whether Mirapex increases the risk of heart failure.” The FDA says health care professionals should continue to follow drug-label recommendations when prescribing Mirapex, and that it is continuing to work with the manufacturer to “clarify further the risk of heart failure with Mirapex.” Read more.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder